Truist Securities analyst Asthika Goonewardene reiterated a Buy rating on Sutro Biopharma (NASDAQ: STRO), and removes PT.The analyst commented: "Luvelta ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE